Blood Serum Diagnostic Test for Mesothelioma Explored in Study

One of the biggest obstacles to treating pleural mesothelioma cancer effectively is its often late-stage diagnosis. A recent study shows encouraging signs that those days could be ending. Novel diagnostic testing using blood serum and infrared spectroscopy is being explored to better characterize and differentiate mesothelioma in its early stages from other lung diseases and benign effusions. The study is being conducted by scientists and doctors in Ankara and Istanbul, Turkey, spread through various hospitals and university medical centers within the region. Biochimica et Biophysica Acta – Molecular Basis of Disease will publish the study in October 2022. Science Direct released an online version June 23. “As the symptoms of mesothelioma usually take decades to become noticeable, timing is the worst aspect of this disease,” co-author Dr. Feride Severcan, Altinbas University Faculty of Medicine, told The Mesothelioma Center at Asbestos.com. “An early diagnosis from easily collected blood serum is a very valuable approach, increasing the chance of successful treatment and survival rate.” Early Diagnosis Allows for More Treatment Options Because of mesothelioma’s typical late-stage diagnosis, less than 25% of pleural mesothelioma patients even qualify for aggressive surgery and the most effective multimodality treatment. The majority of patients diagnosed with pleural mesothelioma receive only standard chemotherapy and have a median survival of 12 ...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Tags: Clinical Trials/Research/Emerging Treatments Diagnosis Pleural Source Type: news